SAR-260301

• Description :

  SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC50 of 23 nM[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  PI3K

• Type :

  Reference compound

• Related Pathways :

  PI3K/Akt/mTOR

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/SAR-260301.html

• Purity :

  99.95

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C1N=C(CC(N2[C@@H](C)CC3=C2C=CC=C3)=O)NC(N4CCOCC4)=C1

• Molecular Formula :

  C19H22N4O3

• Molecular Weight :

  354.40

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Certal V, et al. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN) -deficient cancers. J Med Chem. 2014 Feb 13;57 (3) :903-20.|[2]Bonnevaux H, et al. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor. Mol Cancer Ther. 2016 Jul;15 (7) :1460-71.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  PI3KC2γ; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ; Vps34

• CAS Number :

  [1260612-13-2]